Synopsis
Synopsis
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 7 Ethyl 10 Hydroxycamptothecin
2. 7-ethyl-10-hydroxycamptothecin
3. Camptosar
4. Camptothecin 11
5. Camptothecin-11
6. Cpt 11
7. Cpt-11
8. Cpt11
9. Irinotecan
10. Irrinotecan
11. Nk012 Compound
12. Sn 38
13. Sn 38 11
14. Sn-38
15. Sn-38-11
16. Sn3811
1. 100286-90-6
2. Irinotecan Hcl
3. Topotecin
4. Campto
5. Camptothecin 11 Hydrochloride
6. Camptosar
7. Cpt 11
8. Cpt-11
9. Irinotecan (hydrochloride)
10. Camptothecin 11
11. U 101440e
12. Chebi:5971
13. (s)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate Hydrochloride
14. Camptothecin Analog
15. 06x131e4oe
16. 7-ethyl-10-(4-(1-piperidino)-1-piperidino)carbonyloxy Camptothecin Hydrochloride
17. Nsc616348
18. Nsc-616348
19. Ncgc00095190-01
20. Dsstox_cid_25953
21. Dsstox_rid_81249
22. Dsstox_gsid_45953
23. [(19s)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate;hydrochloride
24. Irinotecan Hydrochloride Anhydrous
25. Cas-100286-90-6
26. U-101440e
27. Unii-06x131e4oe
28. Irinotecan Hydrochloride [usan:jan]
29. Mfcd01862255
30. Irinotecanhydrochloride
31. Cpt-11 Hydrochloride
32. Irinotecan Monohydrochloride
33. Schembl4033
34. Camptosar (tn) (pharmacia)
35. (s)-[1,4'-bipiperidine]-1'-carboxylic Acid, 4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester Hydrochloride
36. Spectrum1505821
37. Chembl541887
38. Dtxsid6045953
39. Hms1922j04
40. Pharmakon1600-01505821
41. Amy24895
42. Bcp17234
43. Irinotecan Hydrochloride (anhydrous)
44. Tox21_111479
45. Hy-16562a
46. Nsc759878
47. S5026
48. Akos015901921
49. Tox21_111479_1
50. Ccg-213561
51. Irinotecan Hydrochloride [who-dd]
52. Ncgc00095190-02
53. Ncgc00178697-04
54. (1,4'-bipiperidine)-1'-carboxylic Acid, (4s)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl Ester, Monohydrochloride
55. (1,4'-bipiperidine)-1'-carboxylic Acid, 3,4,12,14-tetrahydro-4,11-diethyl-4-hydroxy-3,4-dioxo-1h-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl Ester, Monohydrochloride, (s)-
56. Ac-28335
57. As-13304
58. I0714
59. Irinotecan Hydrochloride Anhydrous [mi]
60. Irinotecan Hydrochloride, Topoisomerase Inhibitor
61. 286i906
62. A897508
63. Sr-01000763864
64. Q-100016
65. Sr-01000763864-3
66. Q27106952
67. Z1550648758
68. (+)-7-ethyl-10-hydroxycamptothecine 10-(1,4'-bipiperidine)-1'-carboxylate, Monohydrochloride
69. (1,4'-bipiperidine)-1'-carboxylic Acid, (4s)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl Ester, Hydrochloride (1:1)
70. (19s)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaen-7-yl [1,4'-bipiperidine]-1'-carboxylate Hydrochloride
71. (4s)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylic Acid Ester Hydrochloride
72. (4s)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate Hydrochloride
73. (s)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl[1,4'-bipiperidine]-1'-carboxylatehydrochloride
74. [(19s)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate Hydrochloride
75. [1, 4,11-diethyl-3,4,12, 14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano[3',4':6,7] Indolizino[1,2-b]quinolin-9-yl Ester, Monohydrochloride (s)-
76. [1,4'-bipiperidine]-1'-carboxylic Acid,(4s)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester, Monohydrochloride
77. 1-[1-({[(4s)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl]oxy}carbonyl)piperidin-4-yl]piperidin-1-ium Chloride
1. Camptosar
2. Campto
3. Irinotecan
4. Hy-16562
Molecular Weight | 623.1 g/mol |
---|---|
Molecular Formula | C33H39ClN4O6 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 5 |
Exact Mass | 622.2558127 g/mol |
Monoisotopic Mass | 622.2558127 g/mol |
Topological Polar Surface Area | 113 Ų |
Heavy Atom Count | 44 |
Formal Charge | 0 |
Complexity | 1200 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Irinotecan hydrochloride |
Drug Label | Irinotecan hydrochloride injection is an antineoplastic agent of the topoisomerase I inhibitor class. Irinotecan hydrochloride was clinically investigated as CPT-11. Irinotecan hydrochloride injection is supplied as a sterile, pale yellow, clear, aqu... |
Active Ingredient | Irinotecan hydrochloride |
Dosage Form | Injectable |
Route | injection; Injection |
Strength | 20mg/ml; 100mg/5ml (20mg/ml); 500mg/25ml (20mg/ml); 100mg/5ml; 40mg/2ml (20mg/ml) |
Market Status | Prescription |
Company | Pliva Lachema; Hospira; Teva Parenteral; Fresenius Kabi Oncol; Accord Hlthcare; Jiangsu Hengrui Med; Hikma Farmaceutica; Teva Pharms Usa; Cipla; Hisun Pharm Hangzhou; Sun Pharma Global; Actavis Elizabeth; Emcure Pharms; Mustafa Nevzat Ilac; Fresenius Kabi |
2 of 2 | |
---|---|
Drug Name | Irinotecan hydrochloride |
Drug Label | Irinotecan hydrochloride injection is an antineoplastic agent of the topoisomerase I inhibitor class. Irinotecan hydrochloride was clinically investigated as CPT-11. Irinotecan hydrochloride injection is supplied as a sterile, pale yellow, clear, aqu... |
Active Ingredient | Irinotecan hydrochloride |
Dosage Form | Injectable |
Route | injection; Injection |
Strength | 20mg/ml; 100mg/5ml (20mg/ml); 500mg/25ml (20mg/ml); 100mg/5ml; 40mg/2ml (20mg/ml) |
Market Status | Prescription |
Company | Pliva Lachema; Hospira; Teva Parenteral; Fresenius Kabi Oncol; Accord Hlthcare; Jiangsu Hengrui Med; Hikma Farmaceutica; Teva Pharms Usa; Cipla; Hisun Pharm Hangzhou; Sun Pharma Global; Actavis Elizabeth; Emcure Pharms; Mustafa Nevzat Ilac; Fresenius Kabi |
Topoisomerase I Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE I. (See all compounds classified as Topoisomerase I Inhibitors.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
(S)-8-Ethyl-8-hydroxy-2,3,5,8-tetrahydro-6-oxa-3a-...
CAS Number : 110351-94-5
End Use API : Irinotecan Hydrochloride
About The Company : Cohance Lifesciences is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commer...
2’-Amino-5’-hydroxypropiophenone
CAS Number : 35364-15-9
End Use API : Irinotecan Hydrochloride
About The Company : Cohance Lifesciences is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commer...
7-Ethyl-10-hydroxycamptothecin (SN-38)
CAS Number : 86639-52-3
End Use API : Irinotecan Hydrochloride
About The Company : Cohance Lifesciences is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commer...
2’-Amino-5’-hydroxypropiophenone (AHP)
CAS Number : 35364-15-9
End Use API : Irinotecan Hydrochloride
About The Company : Cohance Lifesciences is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commer...
CAS Number : 4897-50-1
End Use API : Irinotecan Hydrochloride
About The Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for...
CAS Number : 4897-50-1
End Use API : Irinotecan Hydrochloride
About The Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for...
4-Piperidinylpiperidine dihydrochloride
CAS Number : 4876-60-2
End Use API : Irinotecan Hydrochloride
About The Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for...
4-Piperidinylpiperidine dihydrochloride
CAS Number : 4876-60-2
End Use API : Irinotecan Hydrochloride
About The Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for...
CAS Number : 4897-50-1
End Use API : Irinotecan Hydrochloride
About The Company : Established in 2003 with small pilot plant and came in to commercial production in 2013 in the name of Allchem Laboratories, it is an independent privately owne...
CAS Number : 19685-09-7
End Use API : Irinotecan Hydrochloride
About The Company : Chengdu Yazhong Bio-pharmaceutical Co., Ltd., founded in 2002, is a leading company with plant extracts, APIs and medical intermediates. Our company is equipped...
RLD : No
TE Code : AP
Brand Name : IRINOTECAN HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 40MG/2ML (20MG/ML)
Approval Date : 2008-11-21
Application Number : 79068
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : IRINOTECAN HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 100MG/5ML (20MG/ML)
Approval Date : 2020-11-02
Application Number : 213278
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code :
Brand Name : IRINOTECAN HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 100MG/5ML (20MG/ML)
Approval Date : 2010-04-15
Application Number : 78953
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AP
Brand Name : IRINOTECAN HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 100MG/5ML (20MG/ML)
Approval Date : 2008-02-27
Application Number : 77915
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : Yes
TE Code : AP
Brand Name : CAMPTOSAR
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 40MG/2ML (20MG/ML)
Approval Date : 1996-06-14
Application Number : 20571
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AP
RLD : No
TE Code : AP
Brand Name : IRINOTECAN HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 100MG/5ML (20MG/ML)
Approval Date : 2016-05-03
Application Number : 203380
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : IRINOTECAN HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 300MG/15ML (20MG/ML)
Approval Date : 2016-05-03
Application Number : 203380
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : IRINOTECAN HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 40MG/2ML (20MG/ML)
Approval Date : 2008-12-24
Application Number : 78753
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : IRINOTECAN HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 100MG/5ML (20MG/ML)
Approval Date : 2008-12-24
Application Number : 78753
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : IRINOTECAN HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 40MG/2ML (20MG/ML)
Approval Date : 2011-05-13
Application Number : 90393
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Dosage Form : Softgels
Grade : Oral
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2025-05-02
US Patent Number : 8703181
Drug Substance Claim :
Drug Product Claim :
Application Number : 207793
Patent Use Code : U-1434
Delist Requested :
Patent Use Description : TREATMENT OF PANCREATI...
Patent Expiration Date : 2025-05-02
Patent Expiration Date : 2033-06-12
US Patent Number : 9364473
Drug Substance Claim :
Drug Product Claim :
Application Number : 207793
Patent Use Code : U-1856
Delist Requested :
Patent Use Description : TREATMENT OF METASTATI...
Patent Expiration Date : 2033-06-12
Patent Expiration Date : 2033-06-12
US Patent Number : 10980795
Drug Substance Claim :
Drug Product Claim :
Application Number : 207793
Patent Use Code : U-1848
Delist Requested :
Patent Use Description : TREATMENT OF METASTATI...
Patent Expiration Date : 2033-06-12
Patent Expiration Date : 2033-06-12
US Patent Number : 9339497
Drug Substance Claim :
Drug Product Claim :
Application Number : 207793
Patent Use Code : U-1848
Delist Requested :
Patent Use Description : TREATMENT OF METASTATI...
Patent Expiration Date : 2033-06-12
Patent Expiration Date : 2033-06-12
US Patent Number : 11369597
Drug Substance Claim :
Drug Product Claim :
Application Number : 207793
Patent Use Code : U-1848
Delist Requested :
Patent Use Description : TREATMENT OF METASTATI...
Patent Expiration Date : 2033-06-12
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?